• GW 6471: Strategic PPARα Antagonism for Translation

  2026-09-28

  GW 6471 provides a controllable way to interrogate PPARα-dependent transcription across cellular metabolism research, lipid homeostasis studies, and environmental toxicology. This thought-leadership article connects the compound’s co-repressor-based mechanism with findings from a PFHxS zebrafish study and outlines a translational workflow that separates pathway association from causal involvement.

• Flumequine Workflows for Topoisomerase II Research

  2026-09-28

  Use Flumequine to connect topoisomerase II inhibition with cell-growth and cell-death measurements, rather than treating a single viability score as the whole drug response. This practical workflow pairs concentration- and time-resolved testing with handling guidance and assay-specific troubleshooting.

• SNAI1 Drives EMT and Stemness in Thymic Tumors

  2026-09-27

  A 2024 study identifies SNAI1 as a regulator of epithelial–mesenchymal transition and cancer stem cell-like traits in thymic epithelial tumors, linking its transcriptional activity to PIK3R2 and phosphorylated EphA2. Multi-omics and functional experiments support this pathway as a candidate mechanism of tumor progression, while leaving its therapeutic relevance for future validation.

• Hydroxytyrosol in Cardiovascular Mechanism Research

  2026-09-26

  Explore how Hydroxytyrosol can help distinguish redox, inflammatory, and cholesterol-efflux responses in cardiovascular research. This article examines key findings from a recent olive-oil polyphenol study and translates them into evidence-aware experimental decisions.

• JC-1 Mitochondrial Membrane Potential Assay Guide

  2026-09-25

  Connect mitochondrial depolarization measurements to studies of cancer-cell responses and immunomodulatory compounds with a ratiometric JC-1 workflow. Learn how to use CCCP controls, plan a practical pilot, and interpret results without treating membrane potential as a stand-alone measure of cell death.

• Neuromedin S (rat): Practical Assay Guidance

  2026-09-25

  Neuromedin S (rat) provides a defined peptide ligand for controlled studies of neuromedin U receptor signaling, with product-specific information on molecular weight, solubility, and storage. Use it for research assay development with vehicle and handling controls; the supplied information does not establish clinical use, in vivo dosing, or a validated assay concentration.

• 4-MUG Assays for Gaucher Model Functional Readouts

  2026-09-24

  Use 4-Methylumbelliferyl-β-D-Glucopyranoside to convert glucosidase activity into a practical fluorescence readout for lysate assays, enzyme kinetics, and Gaucher disease model studies. The workflow below connects mRNA-driven GCase expression to functional testing while separating enzyme activity from questions of lysosomal localization and disease correction.

• OsALY4 Links m5C Reading to Rice Stress Tolerance

  2026-09-24

  The study identifies OsALY4 as an m5C-mRNA reader that works with the RNA helicase OsAIP2 to support export of selected transcripts from the nucleus. Its findings connect this RNA-processing step with chilling and salt responses in rice, while revealing that OsALY2 and OsALY6 may compensate for loss of OsALY4 under stress.

• IDH1-R132H Autopalmitoylation and Cancer Metabolism

  2026-09-23

  The study identifies C269 autopalmitoylation as a mutation-associated modification that enhances IDH1-R132H activity and connects fatty-acid availability to production of the oncometabolite 2-HG. By combining chemical-probe profiling with functional experiments, the authors show that disrupting this modification reverses several mutant-associated phenotypes, highlighting a potential vulnerability in IDH1-mutant cancers.

• From Galectin-1 to Functional Glucose Uptake

  2026-09-23

  The Galectin-1–FIP200 axis offers a mechanistic framework for hepatic steatosis and insulin resistance, but pathway markers alone do not establish a functional metabolic phenotype. This article explains how the WST-8 Glucose Uptake Assay Kit can connect autophagy-focused biology with quantitative, non-radioactive glucose uptake measurements in translational research workflows.

• Resibufogenin Blocks NLRP3 in Atherosclerosis

  2026-09-22

  The reference study identifies resibufogenin as a candidate inhibitor of NLRP3 inflammasome assembly in atherosclerosis. Using ApoE-/- mice, macrophage-based assays, molecular docking, and surface plasmon resonance, the authors connect binding at NLRP3 CYS-279 with reduced plaque pathology, inflammatory signaling, and foam-cell formation.

• Polybrene Workflows for Mitochondrial Metabolism Studies

  2026-09-22

  Use Polybrene to improve lentiviral, retroviral, or lipid-mediated delivery when building TCAIM–OGDH models, while keeping the enhancer separate from downstream metabolic measurements. This workflow combines practical dose optimization with the native-protein insights of the latest TCAIM study.

• Digoxin Workflows for Cardiac and CHIKV Research

  2026-09-21

  Build reproducible Digoxin assays that connect Na+/K+ ATPase inhibition with cardiac contractility modulation, arrhythmia treatment research, and cell-specific chikungunya models. This guide combines formulation control, dose-response design, translational animal context, and troubleshooting for APExBIO SKU B7684.

• Gemcitabine: A Mechanistic Assay Framework

  2026-09-21

  Gemcitabine is more than a cytotoxic reagent: it can serve as a calibrated perturbation for connecting DNA synthesis failure, checkpoint signaling, and apoptosis. This article applies a transcriptomics-informed assay logic to cancer research, with practical guidance for interpreting Gemcitabine responses without confusing correlation with mechanism.

• SkQ1, Mitochondrial Signalling, and Ovarian Cancer Atrophy

  2026-09-20

  A 2025 Journal of Physiology study used a time-resolved ovarian cancer model and chronic mitochondrial antioxidant treatment to test whether mitochondrial hydrogen peroxide, apoptosis, and necroptosis drive skeletal muscle atrophy. SkQ1 normalized late-stage mitochondrial peroxide emission and caspase activity without rescuing fibre size, indicating that these signals may accompany, rather than cause, type IIB muscle loss.

8059 records 1/538 page Next 12345 下5页 Last page